These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30792408)

  • 1. A platform for glycoengineering a polyvalent pneumococcal bioconjugate vaccine using E. coli as a host.
    Harding CM; Nasr MA; Scott NE; Goyette-Desjardins G; Nothaft H; Mayer AE; Chavez SM; Huynh JP; Kinsella RL; Szymanski CM; Stallings CL; Segura M; Feldman MF
    Nat Commun; 2019 Feb; 10(1):891. PubMed ID: 30792408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production and efficacy of a low-cost recombinant pneumococcal protein polysaccharide conjugate vaccine.
    Herbert JA; Kay EJ; Faustini SE; Richter A; Abouelhadid S; Cuccui J; Wren B; Mitchell TJ
    Vaccine; 2018 Jun; 36(26):3809-3819. PubMed ID: 29778517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae.
    Lin H; Peng Y; Lin Z; Zhang S; Guo Y
    Microb Pathog; 2015; 83-84():35-40. PubMed ID: 25959527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status and perspectives on protein-based pneumococcal vaccines.
    Darrieux M; Goulart C; Briles D; Leite LC
    Crit Rev Microbiol; 2015 Jun; 41(2):190-200. PubMed ID: 23895377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosynthesis of Conjugate Vaccines Using an O-Linked Glycosylation System.
    Pan C; Sun P; Liu B; Liang H; Peng Z; Dong Y; Wang D; Liu X; Wang B; Zeng M; Wu J; Zhu L; Wang H
    mBio; 2016 Apr; 7(2):e00443-16. PubMed ID: 27118590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and protective efficacy of a prototype pneumococcal bioconjugate vaccine.
    Aceil J; Paschall AV; Knoot CJ; Robinson LS; Scott NE; Feldman MF; Harding CM; Avci FY
    Vaccine; 2022 Oct; 40(42):6107-6113. PubMed ID: 36115800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent approaches in vaccine development against Streptococcus pneumoniae.
    Tarahomjoo S
    J Mol Microbiol Biotechnol; 2014; 24(4):215-27. PubMed ID: 25196525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycoengineering bioconjugate vaccines, therapeutics, and diagnostics in E. coli.
    Harding CM; Feldman MF
    Glycobiology; 2019 Jul; 29(7):519-529. PubMed ID: 30989179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering a suite of E. coli strains for enhanced expression of bacterial polysaccharides and glycoconjugate vaccines.
    Kay EJ; Mauri M; Willcocks SJ; Scott TA; Cuccui J; Wren BW
    Microb Cell Fact; 2022 Apr; 21(1):66. PubMed ID: 35449016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purification and characterization of a Shigella conjugate vaccine, produced by glycoengineering Escherichia coli.
    Ravenscroft N; Haeuptle MA; Kowarik M; Fernandez FS; Carranza P; Brunner A; Steffen M; Wetter M; Keller S; Ruch C; Wacker M
    Glycobiology; 2016 Jan; 26(1):51-62. PubMed ID: 26353918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On-line prediction of the feeding phase in high-cell density cultivation of rE. coli using constructive neural networks.
    Nicoletti MC; Bertini JR; Tanizaki MM; Zangirolami TC; Gonçalves VM; Horta AC; Giordano RC
    Comput Methods Programs Biomed; 2013 Jul; 111(1):228-48. PubMed ID: 23566708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation of polysaccharide-conjugate vaccines.
    Peeters CC; Lagerman PR; de Weers O; Oomen LA; Hoogerhout P; Beurret M; Poolman JT; Reddin KM
    Methods Mol Med; 2003; 87():153-74. PubMed ID: 12958455
    [No Abstract]   [Full Text] [Related]  

  • 14. Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine.
    Long SS
    Clin Infect Dis; 2005 Jul; 41(1):30-4. PubMed ID: 15937759
    [No Abstract]   [Full Text] [Related]  

  • 15. Glycoengineered Outer Membrane Vesicles: A Novel Platform for Bacterial Vaccines.
    Price NL; Goyette-Desjardins G; Nothaft H; Valguarnera E; Szymanski CM; Segura M; Feldman MF
    Sci Rep; 2016 Apr; 6():24931. PubMed ID: 27103188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of glycoprotein vaccines in Escherichia coli.
    Ihssen J; Kowarik M; Dilettoso S; Tanner C; Wacker M; Thöny-Meyer L
    Microb Cell Fact; 2010 Aug; 9():61. PubMed ID: 20701771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of pneumococcal polysaccharide conjugate vaccine with long spacer arm.
    Wu D; Ji S; Hu T
    Vaccine; 2013 Nov; 31(48):5623-6. PubMed ID: 24120485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective immunity and gene expression related to pneumococcal glycoconjugate.
    Lee CJ; Li ZM
    Adv Exp Med Biol; 2001; 491():505-14. PubMed ID: 14533818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotype of Streptococcus pneumoniae capsular polysaccharide can modify the Th1/Th2 cytokine profile and IgG subclass response to pneumococal-CRM(197) conjugate vaccines in a murine model.
    Mawas F; Feavers IM; Corbel MJ
    Vaccine; 2000 Dec; 19(9-10):1159-66. PubMed ID: 11137252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability and immunogenicity of an eleven valent mixed carrier Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid or tetanus protein conjugate vaccine in Finnish and Israeli infants.
    Dagan R; Kayhty H; Wuorimaa T; Yaich M; Bailleux F; Zamir O; Eskola J
    Pediatr Infect Dis J; 2004 Feb; 23(2):91-8. PubMed ID: 14872172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.